Advent Therapeutics: Advent gets $3 million grant for development of inhaled vitamin A palmitate for the prevention of BPD in newborns

Advent Therapeutics announced that the company has received a $3 million Small Business Innovation Research (SBIR) Phase 2B grant from the National Institutes of Health for continued development of the company's inhaled vitamin A (retinol) palmitate formulation for the prevention of bronchopulmonary dysplasia (BPD) in newborn infants. According to the company, the grant will fund [...]